Identification of novel senolytic targets and development of Conditionally Active Biologic-based-drug conjugates for targeted senescence-associated secretory phenotype elimination in vivo
Conditionally Active Biologics Targeting Novel Senescence Markers Effectively Eliminate the Senescence-Associated Secretory Phenotype in both In Vitro and in Vivo Models
Protein-associated Chemical Switches Differentially Modulate the Binding Activities of Human Apolipoprotein E Isoforms with Their Receptors and with Amyloid Beta Peptides.
